University of California

City of Hope

Larry Eugene Overman

David A Horne

Sangkil Nam

Jun Xie

Richard Jove

Carl W Cotman

Shikha Snigdha

Marcus Baumann

Claudia Kowolik

Brad Loertscher

Christopher Lincoln

Ricardo Miledi

Richard M Woodward

Yoshinori Murata

Fumitaka Ito

Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.

Dithio ETP derivatives

Use of H3K9me3 modulation for enhancing cognitive function and treating anxiety related disorders is presented. A composition is administered to the subject comprising a therapeutically effective amount of a SUV39H1 inhibitor comprising analogs of ETP69. The therapeutically effective amount is effective in treating cognitive dysfunction in aging and age-related disorders.

Use of H3K9me3 modulation for enhancing cognitive function

Provided herein, inter alia, is the synthesis of ETP derivatives. The uses of the ETP derivatives described herein include treatment of cancer.

ETP derivatives

One aspect of the invention relates to novel isatin derivative compounds and the pharmaceutical composition thereof. Another aspect of the invention relates to methods of using the isatin derivative compounds disclosed herein and the pharmaceutical compositions thereof. In certain embodiments, the method is used to treat a cancer or a tumor in a subject including, without limitation, prostate cancer, melanoma, pancreatic cancer, ovarian cancer, and lymphoma. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the activation of one or more proteins such as EGFR, Erk1/2, Her2/Neu, Jak2, Src, Stat3, Akt, Cyclin B1, and Cdc25C. In certain embodiment, the method is used to treat a condition in a subject that can be regulated by the disruption of microtubule formations.

Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof

Novel phosphinic and phosphonic acid derivatives of pyridine, pyrrole and azepine with utility as antagonists of the GABA.sub.rho receptor are disclosed. These compounds have utility as modulators of the excitability of the central nervous system as mediated by their ability to specifically act on closed-channel binding sites of GABA.sub.rho receptors.

Selective antagonists for GABA.sub.rho receptor

A method of making dendrobatid alkaloids with the formula ##STR1## in which A is either CH.sub.3 or H, and n is an integer from 1-9, and R is CH.sub.2 OH, CHO, ##STR2## and R.sub.1 and R.sub.2 are alkyl groups; and the use of such alkaloids to treat cardiovascular illness.

Growing community of inventors

Corona Del Mar, CA, United States of America

Larry Eugene Overman